Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis.
about
Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosisInhaled antibiotics for pulmonary exacerbations in cystic fibrosisInhaled antibiotics for long-term therapy in cystic fibrosisNebulised anti-pseudomonal antibiotics for cystic fibrosisInhaled Antibiotic Therapy in Chronic Respiratory Diseases.Aerosolized antimicrobial therapy in acutely ill patients.Pseudomonal infection in cystic fibrosis: the battle continues.Lung infections. 3. Pseudomonas aeruginosa and other related species.Inhaled therapeutics for prevention and treatment of pneumoniaNebulized antibiotic therapy: the evidence.Delivery of antibiotics to the respiratory tract: an update.Consensus summary of aerosolized antimicrobial agents: application of guideline criteria. Insights from the Society of Infectious Diseases Pharmacists.Aztreonam (for inhalation solution) for the treatment of chronic lung infections in patients with cystic fibrosis: an evidence-based review.Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides.Inhibition of Pseudomonas aeruginosa exoenzyme expression by subinhibitory antibiotic concentrations.Aerosolized antibiotics in cystic fibrosis: current and future trends.Aerosol antibiotic treatment in cystic fibrosis.Inhaled antibiotics in cystic fibrosis: a review.Is prolonged rotavirus infection a common cause of protracted diarrhoea?Pseudomonas aeruginosa cross-colonization and persistence in patients with cystic fibrosis. Use of a DNA probe.Evidence for using nebulised antibiotics in cystic fibrosis.
P2860
Q24188313-AA7018E6-ADE2-4280-9451-71FF5A1A5605Q24202283-3C0C649A-7DA2-408F-8E6B-AF865F22FA06Q24235635-504D1B5C-5FAE-421B-8E2C-46D517864436Q24247996-60B8D419-BB41-4E4D-961E-762339E940F6Q33755342-7AB468AC-28AB-473A-BCD9-2388201E26B4Q33839762-4DFD47EE-5B55-40A5-A7A5-2CA221539ED6Q34358536-2FA70CD3-732E-4975-9FF2-481EA98737BCQ35532283-119116FD-800B-4ABA-9FF0-3BE2B439BFEBQ35925366-F03DC6A2-2AAC-491F-96F4-EB9498F619FAQ36310044-277F2BC1-E951-4FAF-9A71-DAD0B82EF100Q37564542-A32E21DF-14EC-4A13-87CE-ADF34AF9A745Q37760514-FB485F17-3C55-4F9F-AEA9-29C7450D6131Q37948797-7B4E8BD6-DCBE-4EC2-9996-02F3C42A8398Q38133781-1B791FD6-D99A-4909-9715-27FD063CDC12Q39814763-093E360C-6450-45A8-BC31-A5632ED17A0EQ40065026-5B198D4C-6EB3-4D84-9B7F-A0619A5B2A0CQ40826267-F9B00BD1-E15E-4C45-B44C-CD5718CF7137Q41127253-3839F43D-A4AE-4DBC-835A-2B938AF580DCQ42143890-B9C4EE2A-542E-475B-A802-45AEBB9A9D8AQ42232660-4A40C7C8-B5AC-4575-BA82-9E398D66014EQ43102413-B4D46C68-A0E7-41F7-B3BF-759F05BAF96B
P2860
Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis.
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年学术文章
@wuu
1987年学术文章
@zh-cn
1987年学术文章
@zh-hans
1987年学术文章
@zh-my
1987年学术文章
@zh-sg
1987年學術文章
@yue
1987年學術文章
@zh
1987年學術文章
@zh-hant
name
Efficacy of inhaled amikacin a ...... amikacin) in cystic fibrosis.
@en
Efficacy of inhaled amikacin as adjunct to intravenous combination therapy
@nl
type
label
Efficacy of inhaled amikacin a ...... amikacin) in cystic fibrosis.
@en
Efficacy of inhaled amikacin as adjunct to intravenous combination therapy
@nl
prefLabel
Efficacy of inhaled amikacin a ...... amikacin) in cystic fibrosis.
@en
Efficacy of inhaled amikacin as adjunct to intravenous combination therapy
@nl
P2093
P1476
Efficacy of inhaled amikacin a ...... amikacin) in cystic fibrosis.
@en
P2093
Wedgwood-Krucko J
P304
P356
10.1016/S0022-3476(87)80130-0
P407
P577
1987-10-01T00:00:00Z